Sandbox:Madhu: Difference between revisions

Jump to navigation Jump to search
Madhu Sigdel (talk | contribs)
No edit summary
Madhu Sigdel (talk | contribs)
No edit summary
Line 9: Line 9:


* Creamer (1954) made the first manometric descriptions of DES.
* Creamer (1954) made the first manometric descriptions of DES.
* In [year], [scientist] was the first to discover the association between [risk factor] and the development of [disease name].
* In [year], [gene] mutations were first implicated in the pathogenesis of [disease name].
== Outbreaks ==
* There have been several outbreaks of [disease name], which are summarized below:
== Landmark Events in the Development of Treatment Strategies ==
* In [year], [diagnostic test/therapy] was developed by [scientist] to treat/diagnose [disease name].
== Impact on Cultural History ==
== Famous Cases ==
* The following are a few famous cases of disease name:
== References ==


== Classification of DES ==
== Classification of DES ==
* There is no established system for the classification of DES although it is categorized as one of the major disorders of Peristalsis according to The Chicago Classification v.3.0
* There is no established system for the classification of DES although it is categorized as one of the major disorders of peristalsis according to The Chicago Classification v.3.0.


== Risk Factors ==
== Risk Factors ==
Line 34: Line 19:


=== Pathogenesis ===
=== Pathogenesis ===
* The exact pathogenesis of DES is not fully understood. However, current high-resolution manometric studies suggest impairment of inhibitory myenteric plexus neuron. These neurons use nitric oxide (NO) as neurotransmitter. Hence, these patients may also have dysregulation of endogenous NO synthesis or/and degradation. The final result being premature and rapidly propagated or simultaneous contraction of smooth muscles of distal esophagus.
* The exact pathogenesis of DES is not fully understood. However, current high-resolution manometric studies suggest impairment of inhibitory myenteric plexus neuron. These neurons use nitric oxide (NO) as neurotransmitter. Hence, these patients may also have dysregulation of endogenous NO synthesis or/and degradation. The final result is premature and rapidly propagated or simultaneous contraction of smooth muscles of distal esophagus.

Revision as of 13:33, 29 October 2017


Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Madhu Sigdel

Historical Perspective

Discovery

  • DES was first described by Osgood, in 1889 in 6 patients who presented with chest pain and dysphagia.
  • Creamer (1954) made the first manometric descriptions of DES.

Classification of DES

  • There is no established system for the classification of DES although it is categorized as one of the major disorders of peristalsis according to The Chicago Classification v.3.0.

Risk Factors

  • Common risk factors in the development of Diffuse Esophageal Spasm include Age (60-80 years), presence of GERD, Hypertension, anxiety or depression, and drinks (eg. red wine, very hot or cold liquid or fluid).

Pathophysiology

Pathogenesis

  • The exact pathogenesis of DES is not fully understood. However, current high-resolution manometric studies suggest impairment of inhibitory myenteric plexus neuron. These neurons use nitric oxide (NO) as neurotransmitter. Hence, these patients may also have dysregulation of endogenous NO synthesis or/and degradation. The final result is premature and rapidly propagated or simultaneous contraction of smooth muscles of distal esophagus.